Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

INTRODUCTION: Patients with moderate-to-severe plaque psoriasis who experience poor clinical outcomes, including patients with obesity or prior treatment, need improved treatment options. Risankizumab specifically inhibits interleukin 23 and has demonstrated superior efficacy in active-comparator st...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowley, Jeffrey J., Langley, Richard G., Gordon, Kenneth B., Pinter, Andreas, Ferris, Laura K., Rubant, Simone, Photowala, Huzefa, Xue, Zhenyi, Wu, Tianshuang, Zhan, Tianyu, Beeck, Stefan, Shah, Megha, Warren, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850502/
https://www.ncbi.nlm.nih.gov/pubmed/35050485
http://dx.doi.org/10.1007/s13555-021-00679-6

Ejemplares similares

Ejemplares similares